Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6800616

Title:Treatment of HIV infections
Inventors:Wrenn, Jr., Simeon M.; Danville, CA, USA
Summary:Described herein is a method of treating infection of the human immunodeficiency virus (HIV). The invention relates to a process of administering to an HIV-infected host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Further disclosed is a method of treating an HIV-infected host via the administration of a highly active antiretroviral therapy; along with coadministration to the host of a therapeutic agent described herein. Also provided is a method of ex vivo or in vitro treatment of blood-derived cells, bone marrow transplants, or other organ transplants accordingly.
Abstract:Disclosed is a method of treating an HIV-infected host including administering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of treating an HIV-infected host including administering highly active antiretroviral therapy; and coadministering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of ex vivo or in vitro treatment of blood derived cells, bone marrow transplants, or other organ transplants including treating the blood derived cells, bone marrow transplants, or other organ transplants with a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Kits and compositions useful in the practice of the invention are also disclosed.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6800616
Application Number:US1998000032881
Date Filed:26/02/1998
Date Published:05/10/2004
Assignee:SuperGen, Inc., Dublin, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/12/2020